ITK
ENSG00000113263
Target class
Kinase
Chromosome
5
Approved drugs
3
Clinical candidates (approved and in development)
3
- Approved drugs
- 3
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- Yes
- Target name
- ITK
- Gene name
- IL2 inducible T cell kinase
- Gene symbol
- ITK
- Protein name
- Tyrosine-protein kinase ITK/TSK (EC 2.7.10.2) (Interleukin-2-inducible T-cell kinase) (IL-2-inducible T-cell kinase) (Kinase EMT) (T-cell-specific kinase) (Tyrosine-protein kinase Lyk)
- EMT
- PSCTK2
- LYK
- Gene biotype
- Protein coding
- Gene family
- Pleckstrin homology domain containing|SH2 domain containing|Tec family tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 24
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 16.65
- Tissue specificity (Gini)
- 0.672
- Tissue specificity (tau)
- 0.917
- KEGG gene identifiers
- hsa:3702
- Protein interaction confidence
- 0.869446
- Protein interaction partners
- 56
- R-HSA-202433
- R-HSA-2871809
- End position
- 157255185
- Start position
- 157142933
- Chromosome
- 5
- Strand
- Forward
- Cytoplasm . Nucleus . Note=Localizes in the vicinity of cell surface receptors in the plasma membrane after receptor stimulation.
- Cytosol
Publication evidence
- PubMed 17060314
- Tissue specificity (tau)
- 0.917276
- Expression inequality (Gini)
- 0.672077
Expression in transcripts per million
- Spleen
- 16.65
- Whole Blood
- 10.52
- Small Intestine - Terminal Ileum
- 10.45
- Lung
- 8.9
- Adipose - Visceral (Omentum)
- 3.9
Expression in transcripts per million
- Spleen16.65
- Whole Blood10.52
- Small Intestine - Terminal Ileum10.45
- Lung8.9
- Adipose - Visceral (Omentum)3.9
- Thyroid2.19
- Adipose - Subcutaneous2.14
- Fallopian Tube2.14
- Vagina2.08
- Cervix - Ectocervix1.88
- Colon - Transverse1.83
- Cervix - Endocervix1.75
- Breast - Mammary Tissue1.73
- Stomach1.63
- Artery - Coronary1.48
- Skin - Not Sun Exposed (Suprapubic)1.46
- Prostate1.35
- Testis1.31
- Uterus1.31
- Nerve - Tibial1.25
- Artery - Aorta1.16
- Bladder1.14
- Minor Salivary Gland1.13
- Esophagus - Mucosa1.09
- Skin - Sun Exposed (Lower leg)0.96
And 29 more, listed on the interactive page.
- GO:0006968
- GO:0007165
- GO:0042110
Cellular components
- GO:0005829
- GO:0004715
- GO:0005515
Related records
Trials (318)
- [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
- 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
- A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
- A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
- A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
- A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
- A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
- A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS
- A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
- A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
- A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects
- A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
- A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
- A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
- A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
- A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
- A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors
- A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
Drugs (4)
- Pazopanib Tyrosine-protein kinase ITK/TSK inhibitor
- Pazopanib hydrochloride Tyrosine-protein kinase ITK/TSK inhibitor
- Ritlecitinib TEC family kinase inhibitor
- Ritlecitinib tosylate TEC family kinase inhibitor